About Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company's other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: SNSS
- CUSIP: 86732860
- Previous Close: $4.30
- 50 Day Moving Average: $4.06
- 200 Day Moving Average: $4.14
- 52-Week Range: $2.63 - $6.30
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.04
- P/E Growth: -0.01
- Market Cap: $89.78M
- Outstanding Shares: 20,878,000
- Beta: 1.88
- Net Margins: -1,623.12%
- Return on Equity: -806.43%
- Return on Assets: -111.92%
Companies Related to Sunesis Pharmaceuticals:
- Current Ratio: 2.39%
- Quick Ratio: 2.39%
What is Sunesis Pharmaceuticals' stock symbol?
Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."
When will Sunesis Pharmaceuticals announce their earnings?
Sunesis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.
What are analysts saying about Sunesis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Sunesis Pharmaceuticals stock:
According to Zacks Investment Research, "Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. " (1/19/2017)
Cowen and Company analysts commented, "Sunesis intends to respond to the EMA’s Day 120 questions on vosaroxin for r/r AML." (7/29/2016)
Who owns Sunesis Pharmaceuticals stock?
Sunesis Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Aisling Capital IV, LP (6.20%), Patrick Lee, MD (5.57%), Palo Alto Investors LLC (5.57%), Boxer Capital LLC (2.51%), Vivo Capital LLC (2.39%) and Renaissance Technologies LLC (0.53%). Company insiders that own Sunesis Pharmaceuticals stock include Daniel N Swisher Jr, Dayton Misfeldt and Geoffrey M Parker.
Who bought Sunesis Pharmaceuticals stock? Who is buying Sunesis Pharmaceuticals stock?
Sunesis Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Boxer Capital LLC, Vivo Capital LLC and Renaissance Technologies LLC. Company insiders that have bought Sunesis Pharmaceuticals stock in the last two years include Daniel N Swisher Jr, Dayton Misfeldt and Geoffrey M Parker.
How do I buy Sunesis Pharmaceuticals stock?
Shares of Sunesis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Sunesis Pharmaceuticals stock cost?
One share of Sunesis Pharmaceuticals stock can currently be purchased for approximately $4.30.